Table 2.

Change from baseline of the synovial MRI biomarkers in response to intervention

Biomarker	Fostamatinib (N = 11) vs. placebo (N = 10) at 6 weeks		Fostamatinib (N = 11) vs. adalimumab (N = 10) at 6 weeks		Fostamatinib (N = 6) vs. adalimumab (N = 5) at 24 weeks
	Treatment ratio* (tr) or difference (td) (90% CI)	Two-sided p-value	Treatment ratio* (tr) or difference (td) (90% CI)	Two-sided p-value	Treatment ratio* (tr) or difference (td) (90% CI)	Two-sided p-value
K trans	tr = 0.95 (0.68–1.33)	0.794	tr = 1.92 (1.36–2.72)	0.003	tr = 1.59 (0.95–2.68)	0.137
IRE	tr = 0.86 (0.62–1.18)	0.417	tr = 1.55 (1.12–2.15)	0.031	tr = 1.60 (1.06–2.42)	0.064
IAUC 60	tr = 0.91 (0.66–1.24)	0.603	tr = 1.67 (1.21–2.30)	0.012	tr = 1.57 (0.97–2.54)	0.120
IAUC 120	tr = 0.88 (0.65–1.19)	0.478	tr = 1.67 (1.22–2.28)	0.010	tr = 1.60 (0.98–2.61)	0.116
VEP	tr = 0.85 (0.66–1.08)	0.130	tr = 0.77 (0.60–1.00)	0.053	tr = 1.23 (0.62–2.11)	0.508
ME	tr = 0.95 (0.70–1.28)	0.756	tr = 1.64 (1.20–2.25)	0.012	tr = 1.57 (1.05–2.36)	0.070
v e	n/a	n/a	n/a	n/a	n/a	n/a
v p	tr = 0.90 (0.60–1.29)	0.610	tr = 1.75 (1.21–2.54)	0.016	tr = 1.75 (1.21–2.54)	0.065
RAMRIS synovitis score	td = -2.00 (-3.25–-0.75)	0.023	td = -1.50 (-2.50–0.00)	0.175	td = 2.00 (-0.50–5.00)	0.230
DAS-28 CRP	td = 0.65 (-0.11–1.41)	0.155	td = -0.13 (-0.89–0.64)	0.780	td = -1.48 (-3.43–0.47)	0.200

Based on the response at 6 weeks in the adalimumab group, the standardised response mean for K ^trans was -0.64

DAS-28 CRP Disease Activity Score 28 based on C-reactive protein

*tr is used for VEP and the DCE-MRI endpoints as they are log-normally distributed but td for the RAMRIS synovitis score and DAS-28 CRP which are not:

tr <1 or td < 0 indicate an effect in favour of fostamatinib